Reviva Q2 2022 Earnings Report
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $5.3 million for the second quarter of 2022, with cash totaling $19.4 million as of June 30, 2022. The company is focused on advancing the clinical development of brilaroxazine in the Phase 3 RECOVER study for schizophrenia.
Enrollment is on pace for the ongoing pivotal Phase 3 RECOVER trial.
Topline data for RECOVER evaluating brilaroxazine for schizophrenia is expected in mid-2023.
Cash totaled $19.4 million as of June 30, 2022.
Over 20% of the approximately 400 patients planned already enrolled.
Reviva
Reviva
Forward Guidance
Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of June 30, 2022 will be sufficient to fund its current operating plans through at least March 2023.